HCM
BLRX

Highbridge Capital Management’s BioLineRX BLRX Stock Holding History

Highbridge Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,250
Closed -$215K – 258
2024
Q4 		$215K Buy
+25,250
New +$372K 0.01% 165

Other funds holding BLRX

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Highbridge Capital Management's BLRX Position: Q1 2025 in Review

Highbridge Capital Management sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 25,250 shares — an estimated $215K sold.

Highbridge Capital Management first reported a position in BLRX in Q4 2024 and held it in 1 quarter. The position peaked at $215K in Q4 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

  • Highbridge Capital Management reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 25,250 BioLineRX shares in Q1 2025, an estimated $215K.
  • Highbridge Capital Management first reported a position in BioLineRX in Q4 2024 and held it in 1 quarter.
  • Highbridge Capital Management's BioLineRX position peaked at $215K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Highbridge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.